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priority over surgery, depending on the location and the size of 
the hemorrhage. Moreover, many different surgical methods, ei-
ther tried or being developed, are available. Therefore, clear guide-
lines are needed in this regard.
The Korean Society of Cerebrovascular Surgeons (KSCVS) and 
the Clinical Research Center for Stroke (CRCS) decided to issue 
a Korean version of the guidelines for the medical and surgical 
management of primary ICH as a framework for the treatment 
INTRODUCTION
The ideal treatment of intracerebral hemorrhage (ICH) is to 
minimize on-going neurologic damage including limiting hema-
toma expansion and early management of neurologic complica-
tions. If surgically indicated, removal of the hematoma may be 
considered while minimizing direct brain damage associated with 
the surgery itself. In some cases, conservative treatment may have 
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decision and as a basis for future studies, following the ‘Guideline 
Development Manual’ of CRCS. The Quality Control Commit-
tee (QCC) at the KSCVS and the Writing Group (WG) at the 
CRCS systematically reviewed relevant literature and major 
published guidelines between June 2007 and June 2013 and took 
a developmental strategy of adaptation rather than de novo meth-
ods. Based on the interpretation of the published evidence, rec-
ommendations were made, and the level of evidence and the 
grade of the recommendation were determined using the meth-
ods adapted from those of the CRCS. Though guidelines are also 
needed on ICH secondary to cerebral aneurysm or cerebral ar-
teriovenous malformation which requires surgical removal, only 
primary ICH is covered in the present clinical practice guideline 
(CPG). The latest evidence is reflected in this CPG in a timely 
manner to help physicians and their patients make a decision in 
clinical practice. Therefore, revision of this CPG by newly re-
leased evidence from ongoing trials will be achieved, and sub-
jects that are not covered in this CPG due to insufficient scientif-
ic evidence are believed to be major research topics in the future. 
Lack of domestic references also remains an unsolved issue. The 
authors definitely emphasize and make it very clear that the ulti-
mate discretion is always with the physician in charge who has a 
broad perspective of the various factors in play in each patient. 
The present CPG, therefore, is neither to limit the practice of 
medicine by any healthcare professional, nor to provide refer-
ence for insurance claim evaluation. Furthermore, it should nev-
er serve as a basis for legal judgment for a medical care which was 
provided under a specific clinical situation.
MEDICAL MANAGEMENT OF PRIMARY ICH
Medical management of ICH can be classified into three parts : 
1) blood pressure (BP) control to possibly limit hematoma ex-
pansion, 2) managing intracranial pressure (ICP) crisis, and 3) 
management of seizures. Here, we will review the recent advanc-
es in these issues. 
BP management
Previous recommendations (http://www.stroke-crc.or.kr/popup_ 
090513.html)
The following guidelines are recommended for BP control in 
acute ICH [level of evidence (LOE) : III, Grade of Recommenda-
tion (GOR) : B] (Table 1).
1) For systolic BP (SBP) >200 mm Hg or mean arterial pres-
sure (MAP) >150 mm Hg, measure BP every 5 minutes, and 
lower BP aggressively with intravenous antihypertensives. 
2) For SBP >180 mm Hg or MAP >130 mm Hg with (sus-
pected) ICP elevation, maintain cerebral perfusion pressure 
(CPP) at 60–80 mm Hg, and lower BP with intravenous anti-
hypertensives (bolus or infusion). 
3) For SBP >180 mm Hg or MAP >130 mm Hg without ev-
idence of ICP elevation, clinically evaluate the patient every 15 
minutes, and control BP with intravenous antihypertensives 
(bolus or infusion) to maintain a MAP of 110 mm Hg or SBP/
diastolic BP (DBP) of 160/90 mm Hg.
Recommendations from foreign guidelines 
American Heart Association/American Stroke Association 
(AHA/ASA, USA)52)
1) Until ongoing clinical trials of BP intervention for ICH are 
completed, physicians must manage BP based on the present in-
complete efficacy evidence. Current suggested recommenda-
tions for target BPs in various situations are listed below and may 
be considered (Class IIb; LOE C)
i. If SBP is >200 mm Hg or MAP is >150 mm Hg, then consid-
Table 1. Definition of the evidence level and recommendation grade used in the Korean Society of Cerebrovascular Surgeons and the Clinical Research 
Center for Stroke (http://www.stroke-crc.or.kr/popup_090513.html)
Level of evidence (LOE)
Ia Evidence obtained from the meta-analysis of randomized controlled trials
Ib Evidence obtained from at least one randomized controlled trial
IIa Evidence obtained from at least one well-designed controlled study without randomization
IIb Evidence obtained from at least one other type of well-designed quasi-experimental study
III Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, 
  correlation studies and case studies
IV Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected 
  authorities
Grade of recommendation
A (LOE Ia, Ib) At least one randomized controlled trial as part of the body of literature of overall good quality and consistency 
  addressing a specific recommendation
B (LOE IIa, IIb, III) Availability of well conducted clinical studies but no randomized clinical trials on the topic of the 
  recommendation
C (LOE IV) Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected 
  authorities. Indicates absence of directly applicable clinical studies of good quality
GPP (Good practice points) Recommended best practice based on the clinical experience of the guideline development group
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er aggressive reduction of BP with continuous intravenous infu-
sion, with frequent BP monitoring every 5 minutes.
ii. If SBP is >180 mm Hg or MAP is >130 mm Hg and there 
is the possibility of elevated ICP, then consider monitoring ICP 
and reducing BP using intermittent or continuous intravenous 
medications while maintaining a CPP of ≥60 mm Hg.
iii. If SBP is >180 mm Hg or MAP is >130 mm Hg and there 
is no evidence of elevated ICP, then consider a modest reduc-
tion of BP (e.g., a MAP of 110 mm Hg or a target BP of 160/90 
mm Hg) using intermittent or continuous intravenous medica-
tions to control BP and clinically reexamine the patient every 
15 minutes.
2) In patients presenting with a SBP of 150 to 220 mm Hg, 
acute lowering of SBP to 140 mm Hg is probably safe (Class IIa; 
LOE B) (new recommendation).
New evidences
The previous recommendations on BP management in pa-
tients with acute ICH were mainly based on small observational 
studies. An anecdotal report showed that an admission SBP >200 
mm Hg was associated with hematoma expansion on follow up 
CT scan. Therefore, a SBP <200 mm Hg was initially recommend-
ed as a BP goal38). However, lowering BP may not always be safe 
because the majority of patients have a history of hypertension 
(HT). Considering that the autoregulation curve is shifted toward 
the higher ranges of BP in patients with HT, there is a safety con-
cern regarding the acute reduction of BP. Therefore, a modest 
recommendation was made in the previous guidelines for safety 
reasons. An Initial practice guideline suggested that a SBP <180– 
185 mm Hg with a DBP <105–110 mm Hg was recommended in 
patients with a history of HT, while a SBP <160–170 mm Hg with 
a DBP <95–100 mm Hg was recommended in those without a his-
tory of HT13). Those recommendations were rephrased in terms 
of MAP, and a MAP < 130 mm Hg was suggested in the 1999 and 
2007 American Stroke Association (ASA) guidelines10,11).
After the ASA ICH guideline in 2007, three major clinical tri-
als were published, which focused on the relationship between 
acute BP reduction and clinical outcome. In 2008, Intensive 
blood pressure reduction in acute cerebral hemorrhage Trial (IN- 
TERACT) result came out3). Included patients had acute sponta-
neous ICH diagnosed by CT within 6 hours of onset, an elevated 
SBP (150 to 220 mm Hg), and no definite indication or contrain-
dication to BP control. They were randomly assigned to early in-
tensive BP lowering (a target SBP of 140 mm Hg; n=203) or stan-
dard guideline-based BP management (a target SBP of 180 mm Hg; 
n=201). While the mean proportional hematoma growth after 24 
hours was lower in the intensive group compared to the standard 
treatment group [13.7% vs. 36.3%, absolute difference 22.6%, 
95% confidence interval (CI) 0.6–44.5%; p=0.04], intensive BP-
lowering did not increase the risks of adverse events, but failed 
to improve clinical outcomes at 90 days. Although intensive BP 
reduction may be safe, the absolute difference in hematoma vol-
ume between the two groups was only 1.7 mL, which raised the 
question regarding the effectiveness of intensive BP reduction 
from a practical standpoint. In addition, the majority of patients 
(85% of the intensive group, and 95% of the conventional group) 
were treated with diuretics or vasodilators, which were not com-
monly used for controlling BP in usual practice. Despite these 
limitations, intensive BP reduction may be safely tried in patients 
with acute ICH.
Another study reflecting a real practice pattern came out in 
20105). The Antihypertensive Treatment of Acute Cerebral Hem-
orrhage (ATACH) trial also included patients with acute ICH 
within 6 hours from symptom onset if they had an elevated SBP 
≥170 mm Hg. Patients were randomly allocated into three tiers 
of SBP goals (170 to 200 mm Hg, n=18 ; 140 to 170 mm Hg, n=20; 
or 110 to 140 mm Hg, n=22), and SBPs were controlled with in-
travenous nicardipine infusion. Primary outcomes were treatment 
feasibility and safety up to 72 hours. Serious adverse events were 
observed in one subject (5%) in tier two (SBP 140 to 170 mm Hg) 
and in three subjects (14%) in tier three (SBP 110 to 140 mm Hg). 
However, the safety stopping rule was not activated in any of the 
tiers. Therefore, controlling BP with nicardipine may be safe5). In 
order to explore its clinical utility, a phase 3 clinical trial is cur-
rently underway (ATACH-II)65). 
Recently, the result of the INTERACT II, a phase 3 trial, was 
published2). A total of 2839 patients with acute ICH within 6 hours 
from symptom onset were randomized to two BP goals (a target 
SBP <140 mm Hg within 1 hour vs. SBP <180 mm Hg) if their SBP 
was between 150 mm Hg and 220 mm Hg. The antihypertensive 
drugs were chosen at the discretion of the treating physicians. The 
primary outcome was a combined endpoint of death and major 
disability (mRS 3 to 6) at 3 months. The intensive treatment group 
had a tendency for less death or major disability (52.0%) com-
pared to those in the guideline group (55.6%) (odds ratio with in-
tensive treatment, 0.87; 95% CI, 0.75 to 1.01; p=0.06), which failed 
to reach statistical significance. However, secondary outcome 
with the ordinal analysis on the mRS showed a significantly low-
er mRS with intensive treatment (odds ratio for greater disability, 
0.87; 95% CI, 0.77 to 1.00; p=0.04). Safety outcome was not differ-
ent between the two groups. The main mechanism for the improv-
ed outcomes with rapid intensive BP reduction is still unclear be-
cause there were no significant absolute or relative changes in 
hematoma growth between the two treatment groups. The he-
matoma volume difference between the groups was very small 
(adjusted mean volume, 1.4 mL). 
The major safety concern regarding acute BP reduction is the 
potential for aggravation of ischemic injury due to the possible 
existence of perihematomal penumbra. In order to clarify this is-
sue, a randomized open-label study with blinded evaluation was 
carried out14). The included patients were >18 years of age with 
acute spontaneous ICH within 24 hours after onset, and had a 
SBP greater than 150 mm Hg. Patients were randomized to an 
SBP target of <150 mm Hg (n=39) or <180 mm Hg (n=36) and 
underwent a CT perfusion scan to compare the difference in 
relative cerebral blood flow (rCBF) between the two treatment 
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groups. There was no relationship between the BP change and 
perihematomal rCBF in both treatment groups suggesting the 
safety of acute BP reduction in patients with ICH.
Based on these results, rapid BP reduction to a SBP <140 mm Hg 
in patients with acute ICH is probably safe, and may be benefi-
cial in terms of improving functional outcome. 
New recommendations
1. The suggested BP targets in patients with acute ICH are de-
scribed below (LOE III, GOR B). Drugs that can be used for BP 
control in spontaneous ICH are shown in Table 2 (revised rec-
ommendation).
1) If the SBP is >200 mm Hg or MAP is >150 mm Hg, then 
consider aggressive BP reduction with a continuous intravenous 
infusion of drugs, with frequent BP monitoring every 5 minutes. 
2) If the SBP is >180 mm Hg or MAP is >130 mm Hg and there 
is any possibility of an ICP elevation, then consider ICP moni-
toring and reducing BP using an intermittent or continuous in-
travenous infusion while maintaining a CPP (MAP-ICP) of 50–
70 mm Hg. 
3) If the SBP is >180 mm Hg or MAP is >130 mm Hg and there 
is no evidence of an ICP elevation, then consider a modest reduc-
tion of BP using an intermittent or continuous intravenous infu-
sion (MAP of 110 mm Hg for a BP of 160/90 mm Hg) and clin-
ically reexamine the patient every 15 minutes. 
2. In patients with acute ICH, when the SBP is measured be-
tween 150 and 220 mm Hg, the SBP may be safely lowered to 140 
mm Hg within 1 hour (LOE Ib, GOR A) (new Recommendation).
The management of intracranial pressure elevation 
ICP elevation is one of the most common reasons for second-
ary damage in patients with ICH47). Hematoma expansion, peri-
hematomal edema, or hydrocephalus will further aggravate ICP 
surges. An ICP crisis will result in cerebral herniation and subse-
quently a poor neurologic outcome. Therefore, ICP elevation should 
be properly managed in patients with ICH. 
After the publication of the first Korean version of the ICH 
guideline in 2009, no high quality clinical study has been done 
regarding ICP management in patients with ICH. Meanwhile, 
the ASA ICH guideline was updated based on the results from 
traumatic brain injury (TBI) trials. Therefore, the management 
effect on ICP should be interpreted with great caution in this re-
gard. 
Previous recommendations (http://www.stroke-crc.or.kr/popup_ 
090513.html)
1. Treatment and monitoring at the intensive care unit (ICU) 
is recommended in acute hemorrhage patients because of the 
need for ICP elevation monitoring, BP control, intubation, and 
mechanical ventilation (LOE III, GOR B). 
2. To control an elevated ICP, a gradual treatment should be 
considered. The patient’s head should be elevated by about 30° to 
start with. Limited use of analgesics and/or sedatives may be con-
sidered in patients with pain and/or unstable conditions (LOE IV, 
GOR C).
3. A more aggressive ICP control includes the use of mannitol 
and hypertonic saline solution, CSF drainage via a ventricular 
catheter, neuromuscular blockade, and hyperventilation. In gen-
eral, maintaining a CPP ≥70 mm Hg is recommended along with 
the close monitoring of the ICP and blood pressure (LOE IV, 
GOR C).
Recommendations from foreign guidelines 
1. People with ICH should be monitored by specialists in neu-
rosurgical or stroke care for deterioration in function and referred 
immediately for brain imaging when necessary [Royal College of 
Physicians (RCP), UK 2008, LOE consensus].
2. Patients with a Glasgow Coma Scale (GCS) score of ≤8, those 
with clinical evidence of transtentorial herniation, or those with 
significant intraventricular hemorrhage (IVH) or hydrocephalus 
could be considered for ICP monitoring and treatment. A CPP 
of 50 to 70 mm Hg may be reasonable to maintain depending on 
the status of cerebral autoregulation (AHA/ASA, USA 2010 : Class 
IIb; LOE C).
3. Ventricular drainage as a treatment for hydrocephalus is rea-
sonable in patients with a decreased level of consciousness (AHA/ 
ASA, USA 2010 : Class IIa; LOE B).
4. Corticosteroid should not be used for the treatment of pri-
mary ICH [Scottish Intercollegiate Guidelines Network (SIGN) 
2008 : LOE 1++, GOR B].
5. Intravenous mannitol should not be used routinely for the 
treatment of raised intracranial pressure in patients with primary 
ICH (SIGN 2008 : LOE 1+, GOR B).
New evidences
An accurate ICP measurement is the first step in managing pa-
tients with ICP elevation. Intraparenchymal monitor may better 
reflect perihematomal ICPs, representing a more accurate hemo-
dynamic status in the perilesional area which is vulnerable to sec-
ondary injury. ICP measured by ventricular catheter (VC) repre-
sents global ICP, which is regarded as a gold standard. Given that 
VC can be used to drain cerebrospinal fluid or intraventricular 
hemorrhage, ICP measurement via VC is preferred in patients 
Table 2. Drugs that can be used for BP control in spontaneous intracere-
bral hemorrhage
Drug name Bolus dose Infusion rate
Labetalol 5–20 mg, every 
  15 minutes
2 mg/min 
  (up to 300 mg/day)
Nicardipine No indication 5–15 mg/hour
Esmolol 250 μg/kg, loading dose 25–300 μg/kg per minute
Hydralazine 5–20 mg, every 
  30 minutes
1.5–5 μg/kg per minute
Nipride No indication 0.1–10 μg/kg per minute
Nitroglycerine No indication 20–400 μg/min
BP : blood pressure
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with concomitant IVH. The procedural complication rate is re-
ported to be as high as 3% to 4% including procedural hemor-
rhage and catheter related infection24). 
The frequency and risk factors for ICP crisis in patients with 
ICH remains to be elucidated. In small randomized studies, an 
initial ICP, measured at the time of VC insertion, was not direct-
ly associated with the IVH volume or parenchymal ICH vol-
ume79). Moreover, the mean daily ICP was not correlated with 
hemorrhage burden79). Although the existence of IVH per se does 
not mean an ICP crisis, the presence of IVH is considered to be 
associated with poor prognostic factors, probably mediated by 
hydrocephalus. In the International Surgical Trial in Intracere-
bral Haemorrhage (STICH) trial, 377 (42%) out of 902 patients 
had IVH, and a total of 208 (23% among the study patients; 55% 
of the patients with IVH) developed hydrocephalus. Favorable 
functional outcomes at 6 months occurred in 15% and 31% of 
the patients with and without IVH (p<0.00001), respectively, sug-
gesting an association between the presence of IVH and func-
tional outcome44). Moreover, if hydrocephalus is combined in pa-
tients with IVH, the percentage of favorable outcomes drops 
from 20% to 12% (p<0.031). Therefore, the presence of hydro-
cephalus is considered as an important prognostic factor7). In ad-
dition, the presence of IVH is accepted as an important prognos-
tic factor to predict mortality at 1 month and functional recovery 
at 12 months, which is reflected in the ICH score17,27,28). Therefore, 
ICP measurement is necessary, especially in patients who have 
IVH or hydrocephalus, and the insertion of VC may be consid-
ered when their mental status deteriorates as hydrocephalus de-
velops. 
The indications of ICP monitoring is still unclear, but it may be 
tried in ICH patients with significant severity (GCS score of 3 to 
8), based on the TBI guideline in 20088,57). ICP monitoring is need-
ed in patients with huge supratentorial lesions because those pa-
tients are at high risk for transtentorial herniation with second-
ary brainstem compression4,64). Therefore, patients with clinical 
signs of transtentorial herniation may be a good candidate for ICP 
monitoring. 
If ICP can be measured, CPP can be calculated from the dif-
ference between MAP and ICP. It is still debatable regarding 
which ranges of CPP should be pursued in patients with ICH. 
The AHA/ASA ICH guideline in 2007 suggested that CPP should 
be maintained greater than 70 mm Hg, and the target level was 
lowered to a CPP of 50 to 70 mm Hg in 201052). Those recommen-
dations are adapted from the 2007 TBI guideline from the brain 
trauma foundation. It recommended that a CPP lower than 50 
mm Hg should be avoided (Level III) and not be maintained 
greater than 70 mm Hg (Level II)9). The lower limit of CPP (>50 
mm Hg) is based on a small study. In patients with severe TBI 
with a depressed CPP level around 32 mm Hg, if the CPP was el-
evated up to 68 mm Hg with the proper use of pressors, the par-
tial brain tissue oxygen pressure (PbtO2) improved. Based on 
the fact that the PbtO2 level is associated with a poor functional 
outcome, a low CPP should be avoided as well39). Moreover, in a 
small observational study using microdialysis, when the CPP 
dropped below 50 mm Hg, the lactate/pyruvate ratio surged, re-
flecting a metabolic crisis and anaerobic shift of brain glucose 
metabolism61). Taken together, a CPP less than 50 mm Hg should 
be avoided9). The upper range of the CPP at 70 mm Hg is also 
based on studies in patients with severe TBI66). Severe TBI pa-
tients were randomized to either a CPP >70 mm Hg or a CPP 50– 
70 mm Hg, and the frequency of sustained jugular venous desat-
uration (JvSO2) <50% more than 10 minutes, was less in patients 
with higher CPP goals (CPP >70 mm Hg), while the functional 
outcome was not different. However, the development of acute 
respiratory difficulty syndrome was 5 times more frequent in the 
higher CPP group because of prolonged use of pressors with 
high fluid therapy66). Therefore, a CPP >70 mm Hg is not rou-
tinely recommended in patients with TBI9). However, no studies 
have been performed in patients with ICH targeting CPP ranges, 
and the recommendations on CPP ranges were extrapolated 
from a TBI guideline. A small study using comatose ICH patients 
showed that a CPP >80 mm Hg may be beneficial in terms of 
maintaining better brain tissue oxygenation, which needs to be 
confirmed in large numbers of patients41). Therefore, it is still un-
clear which CPP goal should be suggested in patients with ICH.
A variety of methods have been tried in lowering ICPs, includ-
ing hyperventilation, osmotic agents (mannitol and hypertonic 
saline) and therapeutic hypothermia. Based on a study compar-
ing the effectiveness of osmotic agents on ICP management us-
ing equi-osmolar doses, mannitol is considered to be equivalent 
to hypertonic saline. However, recent meta-analysis suggests that 
hypertonic saline has a tendency for better ICP control31). In re-
fractory cases, therapeutic hypothermia (targeting body temper-
ature down to 33 to 35°C) may be tried to manage an ICP crisis. 
The effect of hypothermia on ICP lowering is considered to be 
comparable to osmotic therapy67). Although some reports sug-
gest that therapeutic hypothermia may decrease perihematomal 
edema, systemic infection including pneumonia is one of the 
common adverse events. Therefore, use of therapeutic hypother-
mia in ICH patients should be individualized42). 
New recommendations
1. It is recommended that patients with acute ICH are treated 
in the intensive care unit for the monitoring of the ICP and BP 
and possible need for mechanical ventilation or intubation (LOE 
III, GOR B) (revised recommendation).
2. Patients with a GCS score of ≤8, those with clinical evidence 
of transtentorial herniation, or those with significant IVH or hy-
drocephalus should be considered for ICP monitoring and treat-
ment (LOE III, GOR B) (new recommendation).
3. Ventricular drainage as a treatment for hydrocephalus is rea-
sonable in patients with a decreased level of consciousness (LOE 
III, GOR B) (new recommendation).
4. To control an elevated ICP, a gradual treatment should be 
considered. The patient’s head should be elevated by approxi-
mately 30°. Limited use of analgesics and/or sedatives may be 
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considered in patients with pain and/or unstable conditions 
(LOE IV, GOR C).
5. For more aggressive ICP control, the use of mannitol and 
hypertonic saline solution, neuromuscular blockade, hyperven-
tilation, or therapeutic hypothermia may be tried (LOE IV, GOR 
C) (Revised Recommendation)
Management of seizure 
Seizure is one of the common neurologic complications in pa-
tients with ICH77). It is more common in patients with ICH com-
pared to those with ischemic stroke, and occurs at or within 48 
hours after onset. Seizure may be associated with the aggravation 
of the midline shift and neurologic deterioration; however, its 
causal relationship has not been clearly demonstrated. 
Previous recommendations (http://www.stroke-crc.or.kr/popup_ 
090513.html) 
1. Post-cerebral hemorrhage seizures should warrant the use 
of proper anticonvulsants (LOE Ib, GOR A).
2. A short-term use of anticonvulsants immediately following 
a lobar hemorrhage may decrease the risk of early seizures and is 
recommended (LOE IIa, GOR B).
3. Anticonvulsants used in cerebral hemorrhage should be 
gradually discontinued if no recurrence is observed. In the case 
of recurrence, chronic therapy may be considered (LOE IV, 
GOR C).
Recommendations from foreign guidelines
1. AHA/ASA52)
1) Clinical seizures should be treated with antiepileptic drugs 
(Class I; LOE A) (revised from the previous guideline).
2) Continuous electroencephalogram (EEG) monitoring is 
probably indicated in ICH patients with depressed mental status 
out of proportion to the degree of brain injury (Class IIa; LOE B).
3) Patients with a change in mental status who are found to 
have electrographic seizures on the EEG should be treated with 
antiepileptic drugs (Class I; LOE C). 
4) Prophylactic anticonvulsant medication should not be used 
(Class III; LOE B) (new recommendation).
New evidences
The incidence of seizure after ICH is highly variable depend-
ing on the study population or the definition of seizure. Howev-
er, clinical seizure is reported to be as high as 5% to 19% in pa-
tients with ICH within one week after onset1,16,19,63). Moreover, 
electrographic seizure is four times more common than clinical 
seizure16,75). In addition, 39% of patients who had electrographic 
seizures actually have a non-convulsive status epilepticus. 
The risk factors for the development of seizures after ICH are 
as follows : lobar in location1,19), involvement of the cortex19), and 
hematoma expansion16). Although seizure is believed to be asso-
ciated with rapid aggravation of mass effect and neurologic dete-
rioration in patients with ICH, the causal relationship is ques-
tionable75). Even with the development of seizures, its direct effect 
on poor neurologic outcome or mortality is not clear16,19). 
Recently, a secondary analysis was performed using a placebo 
group from the Cerebral Hematoma and NXY Treatment (CHA- 
NT) trial, which showed that the odds for poor neurologic out-
come at 90 days (mRS 5 or 6) was 6.8 in patients with prophylac-
tic treatment using antiepileptic drugs (95% CI 2.2–21.3), sug-
gesting the harmful effect of the prophylactic use of antiepileptic 
drugs46). However, the majority (78%) of patients was treated with 
phenytoin; hence; it is not clear whether a new generation antiep-
ileptic drugs have similar safety concerns. 
In a recent randomized trial, valproic acid (VPA) prophylaxis 
(n=36) did not prevent the occurrence of seizures compared to 
the placebo (n=36) in patients with spontaneous ICH22). How-
ever, the VPA treated group did not show a poor neurologic out-
come. Therefore, it is still not clear whether the use of antiepilep-
tic drug, except for phenytoin, is associated with a poor neurologic 
outcome. 
In summary, the development of clinical seizure after ICH is 
probably not a cause of neurologic deterioration in patients with 
ICH. Moreover, the prophylactic use of antiepileptic drugs in 
ICH may be associated with a poor outcome, although it is still 
unclear whether other new generation drugs have similar safety 
concerns. Therefore, the prophylactic use of antiepileptic drugs 
without considering individual seizure risk is discouraged. How-
ever, if clinical seizure develops, it is reasonable to treat convul-
sive seizures with the appropriate antiepileptic drugs 
New recommendations 
1. Clinical seizures should be treated with the appropriate an-
tiepileptic drugs (LOE Ib, GOR A) (revised recommendation). 
2. If the patient’s mental status is depressed out of proportion 
to the degree of brain injury, EEG monitoring (continuous EEG, 
more preferably) is needed to exclude the possibility of electro-
graphic seizures. Patients who are found to have electrographic 
seizures on the EEG should be treated with antiepileptic drugs 
(LOE III, GOR B) (new recommendation). 
3. The prophylactic use of antiepileptic drugs should be indi-
vidualized based on the seizure risk, and potential harmful effects 
of antiepileptic drugs. The use of antiepileptic drugs in all patients 
without considering seizure risk is not recommended (LOE IIa, 
GOR B) (new recommendation). 
SURGICAL MANAGEMENT OF PRIMARY ICH
Previous recommendations (http://www.stroke-crc.or.kr/ popup_ 
090513.html)
1. If cerebral herniation is suspected or if loss of consciousness 
is rapid, an early craniotomy may be considered (LOE : IV, GOR : 
C).
2. A craniotomy should be considered for a lobar hemorrhage 
located within 1 cm from the surface with a consciousness level 
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of GCS 9–12 (LOE : IIb, GOR : B).
3. A craniotomy is recommended for a cerebellar hemorrhage 
of 3 cm in diameter or for symptoms suggestive of brainstem 
compression or hydrocephalus (LOE : IIb, GOR : B).
4. For hemorrhages located deep inside the brain, non-crani-
otomy surgery may be considered (LOE : IV, GOR : C).
5. For intraventricular hemorrhages, thrombolysis via ventric-
ular puncture may be considered (LOE : IV, GOR : C).
Recommendations from foreign guidelines
1. AHA/ASA52)
1) Recommendation for the management of IVH
i. Although intraventricular administration of recombinant 
tissue-type plasminogen activator (tPA) in IVH appears to have 
a fairly low complication rate, the efficacy and safety of this treat-
ment is uncertain and considered investigational (Class IIb; 
LOE B).
2) Recommendations for clot removal
i. For most patients with ICH, the usefulness of surgery is un-
certain (Class IIb; LOE C). Specific exceptions to this recom-
mendation follow.
ii. Patients with cerebellar hemorrhage who are deteriorating 
neurologically or who have brainstem compression and/or hy-
drocephalus from ventricular obstruction should undergo surgi-
cal removal of the hemorrhage as soon as possible (Class I; LOE 
B). Initial treatment of these patients with ventricular drainage 
alone rather than surgical evacuation is not recommended (Class 
III; LOE C). 
iii. For patients presenting with lobar clots >30 mL and with-
in 1 cm of the surface, evacuation of the supratentorial ICH by a 
standard craniotomy might be considered (Class IIb; LOE B). 
iv. The effectiveness of minimally invasive clot evacuation uti-
lizing either stereotactic or endoscopic aspiration with or with-
out thrombolytic usage is uncertain and considered investiga-
tional (Class IIb; LOE B). 
v. Although theoretically attractive, no clear evidence at pres-
ent indicates that ultra-early removal of the supratentorial ICH 
improves functional outcome or mortality rate. A very early cra-
niotomy may be harmful due to increased risk of recurrent bleed-
ing (Class III; LOE B). 
2. The Japan Stroke Society (Japan)[http://www.jsts.gr.jp/jss08.
html (Japanese, translated)]
1) Surgery is not indicated for patients with a small amount of 
hematoma less than 10 ml or with mild neurologic deficits (Grade 
D). There is no evidence for clot removal in patients with a level 
of consciousness of 300 on the Japan Coma Scale III (Grade C2). 
2) Putaminal hemorrhage : Surgery should be considered for 
putaminal hemorrhage with moderate neurologic deficits or a 
high grade of compression due to hematoma over 30 mL (Grade 
C1). Especially, stereotactic clot removal is recommended in a 
case accompanied by a level of consciousness of 20–30 on the Ja-
pan Coma Scale II (Grade B). 
3) Thalamic hemorrhage : There is no evidence for clot removal 
as an acute management (Grade C2). For severe ventricular en-
largement as a result of ventricular rupture, ventricular drainage 
may be considered (Grade C1).
4) Subcortical hemorrhage : Surgery may be considered for a 
hematoma located 1 cm or less in depth from the cortical surface 
(Grade C1). A craniotomy is recommend as a surgical method 
(Grade C1).
5) Cerebellar hemorrhage : Surgery is indicated when there is 
neurologic deterioration or hydrocephalus due to compression 
of the brain stem in the case of a cerebellar hemorrhage 3 cm or 
longer in maximal diameter (Grade C1).
6) Brain stem hemorrhage : There is no evidence for clot re-
moval in the acute stage of brain stem hemorrhage (Grade C2). 
Ventricular drainage may be considered when ventricular hem-
orrhage, as a result of brain stem hemorrhage, is the main lesion 
with enlarged ventricles (Grade C1).
7) IVH in adults : Evaluation of the cause of IVH is desirable 
when a vascular abnormality is suspected (Grade C1). Ventricu-
lar drainage should be considered when acute hydrocephalus is 
suspected (Grade C1).
3. European Stroke Initiative (EUSI, Europe)68)
1) Consider a craniotomy if there is deterioration in conscious-
ness (from a GCS level of between 12 and 9 to 8 or lower), if the 
ICH is superficial (the clot is subcortical ≤1 cm from the surface 
and does not reach the deep basal ganglia) or if it is located in the 
cerebellum (Level C recommendation).
2) Deep-seated haematomas do not benefit from a cranioto-
my. Stereotaxic aspiration may be considered, especially if mass 
effect is present (Class IV evidence).
3) External ventricular drainage (EVD) for hydrocephalus can 
be ventricular or via the lumbar route if it is a communicating 
type of hydrocephalus. Lumbar drainage is definitely contra-in-
dicated with all types of obstructive hydrocephalus or if the aeti-
ology is in doubt (Class IV evidence).
4) Intraventricular thrombolysis trials may be considered if an 
EVD becomes necessary but not in infants (Class IV evidence).
New evidences
Removal of hematoma using a craniotomy 
The result of a large multicenter trial, the STICH trial44), which 
randomized 1033 patients from 107 centers over an 8-year peri-
od, beginning in 1995, was published in 2005. The inclusion cri-
teria were 1) randomization within 72 hours and operation with-
in 96 hours of ictus, 2) a clot over 2 cm in diameter, and 3) GCS 
score of 5 or more. Randomization was done to either early sur-
gery or initial medical management if the neurosurgeon was not 
sure of the benefit of surgery. The primary end point of this study 
was the extended Glasgow Outcome Scale (GOS) at 6 months, 
and the secondary end point was the mortality, mRS and BI at 6 
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months. Five hundred six patients were randomized to surgery 
and 530 to medical therapy, with groups being well matched for 
all known variables. In an intention-to-treat analysis, surgery 
within 96 hours of ictus was associated with a statistically insig-
nificant absolute benefit of 2.3% (95% CI–3.2% to 7.7%) in a 6- 
month prognosis-dichotomized extended GOS. The mortality 
[absolute benefit 1.2% (-4.9% to 7.2%)], mRS [absolute benefit 
4.7% (-1.2% to 10.5%)], and BI [absolute benefit 4.1% (-1.4% to 
9.5%)] showed similar statistically insignificant trends in favor of 
surgery. However, 26% of the medical arm ultimately crossed over 
to surgery because of rebleeding or neurological deterioration, 
and a craniotomy was performed in 85% of those crossed-over 
subjects. In contrast, only 75% of the patients in the primary sur-
gical arm underwent a craniotomy, with the others being treated 
with less invasive surgical techniques. Ninety-three percent of 
the patients were available for analysis at 6 months. In addition, 
several subgroup analyses were performed using the age, GCS, 
location and amount of hematoma, distance from cortical sur-
face, surgical method, severity of hemiplegia or aphasia, addi-
tional fibrinolytic therapy, and participating countries, which 
failed to show any statistically significant differences between the 
subgroups. However, the subgroup analysis identified that those 
subjects with a GCS score of 9 to 12, and those with a lobar hem-
orrhage with clots <1 cm from the surface may have been helped 
by an early craniotomy, although this did not reach statistical sig-
nificance. The STICH II trial45) started from a subgroup analysis 
of STICH I, which suggested benefits of early surgery for patients 
with a superficial lobar ICH, relative to the initial medical treat-
ment. The STICH II included 601 patients who had a spontane-
ous lobar ICH with 10 to 100 mL on the CT (1 cm or less from 
the cortical surface of the brain), were within 48 hours of ictus, 
and had a best motor score with a GCS score of 5 or 6, and a best 
eye score of 2 or more. They were randomly assigned to early 
surgery or initial medical treatment. Of these patients, 291 as-
signed to undergo early hematoma evacuation within 12 hours 
of randomization, and 286 assigned to initial medical treatment 
were included in this analysis. The primary outcome was a prog-
nosis-based favorable or unfavorable outcome dichotomized from 
the extended GOS at 6 months after randomization. Overall, 59% 
of the patients in the early surgery group had an unfavorable out-
come at 6 months, compared with 62% of the initial medical treat-
ment group, which was, however, statistically insignificant. Mor-
tality, the secondary outcome, showed a reduction in the early 
surgery group, but this finding was also statistically insignificant. 
However, the subgroup analyses revealed a significant 51% rela-
tive benefit of early surgery for patients with an initial poor prog-
nosis with a GCS score of 9–12. The STICH II concluded that 
early surgery did not increase mortality or morbidity at 6 months 
and might have a small but clinically relevant survival advantage 
for patients with primary superficial ICH without IVH. Howev-
er, there was a large crossover in the initial medical treatment 
group. In STICH II, 62 (21%) of 291 patients initially assigned to 
medical treatment later deteriorated and underwent surgery. Al-
though this group of crossovers had generally poor outcomes, the 
delayed surgery could have prevented mortality and masked the 
benefits of early surgery in this kind of intention-to-treat analysis.
Other small randomized controlled trials (RCTs) regarding 
the negative results of surgical treatment for primary ICH have 
also been reported30,51,80). They did not show significant improve-
ment in the prognosis after surgical treatment for primary ICH 
in their RCTs for supratentorial ICH. Teernstra et al.71) also did 
not provide reasonable evidence for the advantage of surgical 
treatment for supratentorial ICH in their meta-analysis of 9 RCTs 
including STICH. In contrast, a randomized study including 108 
patients with supratentorial subcortical or putaminal ICH >30 
mL in volume assigned to craniotomy or medical management 
within 8 hours of onset showed a better outcome (good recovery 
or moderate disability on the GCS score at 1 year) in those treat-
ed with surgery62). However, this study showed no difference in 
the overall survival and had the limitation of having a small ICH 
volume in the patients. However, recently, individual patient 
data subgroup meta-analysis of surgery for spontaneous supra-
tentorial ICH has been published23). This study included 2186 
cases from 8 studies. Improved outcome with surgery was re-
ported if surgery was undertaken within 8 hours of ictus, or the 
volume of hematoma was 20 to 50 mL, or the GCS score was be-
tween 9 and 12 in this meta-analysis. In addition, there was weaker 
evidence that more superficial hematomas with no IVH might 
also be beneficial23). 
Nonrandomized clinical studies have consistently reported 
good outcomes for surgically treated patients with a cerebellar 
ICH larger than 3 cm in diameter or those with brainstem com-
pression or hydrocephalus, whereas similar patients treated med-
ically resulted in bad outcomes18,36,40,53,69,73). Moreover, EVD alone 
instead of hematoma evacuation is not generally recommended, 
especially in patients with compressed cisterns73). Surgical evac-
uation of thalamic and pontine ICH has been known to be lim-
ited33,35,53).
The timing of the operation remains controversial. Clinical 
studies have reported wide variability in the timing of the surgery, 
ranging from within 4 hours up to 96 hours from the onset of 
symptoms to the time of the operation44,51,62,80). In a retrospective 
study, Kaneko et al.34) reported on the surgical results of 100 pu-
taminal ICHs within 7 hours of symptom onset among which 
sixty were within 3 hours of onset. Seven (7%) had died, whereas 
15 (15%) had fully recovered, and 35 (35%) were living indepen-
dently at home at 6 months after the surgery. However, subse-
quent randomized trials in which surgery was performed within 
12 hours of onset showed mixed results51,62,80). The main flaw of 
early surgery was an increased risk of rebleeding which was not-
ed in the small trial of subjects randomized within 4 hours of on-
set50). Trials that randomized patients into surgery within 24 hours70), 
48 hours6,30), 72 hours72,76), and 96 hours44) have also shown no clear 
benefit for surgery compared with the initial medical manage-
ment.
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Minimally invasive surgical removal of hematoma 
The rationales for minimally invasive surgery for primary 
ICH are 1) possibility for earlier evacuation in the clinical set-
ting, 2) less operation time, 3) reduced trauma to the surround-
ing brain tissue, especially for deep seated ICH, and 4) perfor-
mance under local anesthesia. In contrast, the disadvantages are 
1) potential rebleeding due to the use of fibrinolytics, and 2) in-
creased risk of infections related to prolonged indwelling cathe-
ters. The techniques for minimally invasive clot removal include 
stereotactic aspiration with or without thrombolytic or fibrino-
lytic clot lysis and endoscopic aspiration.
In their randomized study of 490 patients with putaminal ICH 
and moderate degree of neurological status, Hattori et al.26) re-
ported that stereotactic evacuation of the hematoma resulted in 
a lower mortality rate and better recovery to functional indepen-
dence in patients with neurological Grade 3 (eyes are closed but 
open to strong stimuli). More recently, Wang et al.76) reported on 
the results of a multicenter, randomized control clinical trial com-
prised 465 cases of hemorrhage in the basal ganglion from 42 
hospitals in China. Three hundred and seventy-seven patients 
with basal ganglia ICH were randomized to minimally invasive 
craniopuncture therapy (n=195) or conservative control treat-
ment (n=182). They evaluated neurological impairment on the 
14th day after treatment, activities of daily living at the end of the 
3rd month and the case fatality within 3 months. Improvement 
of neurological function in the minimally invasive craniopunc-
ture group was significantly better than that in the control group 
on the 14th day. At 3 months, there was a significant difference 
between the two groups in the score for activities of daily living. 
The proportion of dependent survival patients (mRs >2) in the 
craniopuncture group (40.9%) was significantly lower than that 
in the conservative group (63.0%) at the end of the 3rd month. 
There was no significant difference in the cumulative fatality rates 
within 3 months between the two groups (6.7% in the cranio-
puncture group and 8.8% in the conservative group). Along with 
these randomized studies, a number of nonrandomized studies 
using the stereotactic aspiration reported aspiration rates rang-
ing from 30% to 90% of the initial hematoma6,12,32,37) and rebleed-
ing rates comparable to those seen with conventional cranioto-
my ranging from 0% to 10%6,12,32,37,59,60).
For the Stereotactic Treatment of ICH by means of a Plasmin-
ogen Activator (SICHPA), the multicenter randomized con-
trolled trial (n=71 patients) tried the utility of stereotactic infu-
sion of 5000 IU of urokinase every 6 hours for a maximum of 48 
hours within 72 hours of ictus72). The inclusion criteria were 45 
years or older, the amount of clot ≥10 mL, a Glasgow Eye Motor 
score between 2 and 10, at least one pupil reactive to light, and a 
normal coagulative status (corrected if necessary). Primary end 
points were death and the degree of functional handicap (mea-
sured with mRS) at 6 months. Overall, the mortality at 6 months 
was 57% ; this included 56% in the surgical group and 59% in the 
nonsurgical group. A significant reduction in ICH volume was 
achieved by the surgery (10% to 20%). Logistic regression anal-
ysis indicated the possibility of efficacy for surgical treatment, 
but this was not statistically significant (odds ratio, 0.23). The 
odds ratio of mortality combined with the mRS 5 at 180 days was 
also not statistically significant (odds ratio, 0.52). Since urokinase 
became unavailable in the United States because of reports of 
potential viral contamination during pharmacological prepara-
tion in 1999, tPA has been used in the treatment of ICH10,71). Ves-
pa et al.74) published the phase-2 safety trial for frameless stereo-
tactic aspiration and thrombolysis for 28 patients with ICH in 
the deep basal ganglia and internal capsule with a volume >5 mL. 
After a confirmatory CT scan to localize the catheter, 1 mg of re-
combinant tPA was injected into the center of the hematoma, 
permitted to bathe the clot for 30 minutes, and then drained into 
a closed circuit collection system. tPA was infused every 8 hours 
for 48 hours. They concluded that frameless stereotactic aspira-
tion and thrombolysis of deep spontaneous ICH was a safe ther-
apy that was associated with a reduction in the ICH volume, the 
early improvement in the National Institute of Health Stroke 
Scale (NIHSS) and potentially could be used to improve the out-
come. Given these results, Minimally Invasive Stereotactic Sur-
gery with rtPA for ICH Evacuation (MISTIE) study, a multicenter, 
randomized, controlled and stratified study comparing the ad-
ministration of tPA into the clot cavity versus conventional med-
ical treatment has recently been launched, and preliminary pos-
itive results have been published, reporting that the average clot 
reduction in the acute treatment phase for the surgery arm was 
46% (versus the medical arm 4%) and that recorded adverse 
events were within safety limits, including a 30-day mortality of 
8%, symptomatic rebleeding of 8%, and bacterial ventriculitis of 
0%49).
The MISTIE phase II trial was designed and was done from 
2005 to 2012 to find the safety and efficacy of using minimally in-
vasive surgery with recombinant tPA. In the presentation at the 
International Stroke Conference 2013 reporting the results of 
MISTIE II, the authors reported that minimally invasive surgery 
with recombinant tPA showed 14% improvement in the group 
with a mRS 0–2, 38 fewer days for the hospital stay, savings of 
$44000 USD per patient, and 14% less subjects in long-term care 
for 365 days compared to the medical management group (un-
published yet). The MISTIE II investigators also reported that 
hematoma evacuation was associated with a significant reduc-
tion in perihematomal edema, one of the major causes for sec-
ondary neurologic exacerbation after ICH, and that perihemato-
mal edema does not seem to be exacerbated by recombinant tPA54).
A controlled randomized study of endoscopic evacuation ver-
sus medical treatment was performed in 100 patients with spon-
taneous supratentorial intracerebral (subcortical, putaminal, and 
thalamic) hematomas6). The inclusion criteria for this study were 
1) patients’ age between 30 and 80 years, 2) a hematoma volume 
of more than 10 mL, 3) the presence of neurological or conscious-
ness impairment, 4) the appropriateness of surgery from a medi-
cal and anesthesiological point of view, and 5) the initiation of 
treatment within 48 hours after hemorrhage. Endoscopic hema-
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toma removal could lower mortality in the patients with a hema-
toma volume ≥ 50 mL, and improve functional recovery in surgi-
cal patients with hematomas smaller than 50 mL. These effects 
from surgery in this study were limited to patients aged ≤60 years 
in a preoperatively alert or somnolent state and with a lobar he-
matoma. A larger volume study will clarify the benefit of endo-
scopic aspiration of the hematoma in patients with supratentori-
al ICH. Another prospective randomized study for spontaneous 
basal ganglia hemorrhage was performed to evaluate the safety, 
neurological outcomes, and cost-effectiveness of three surgical 
procedures : endoscopic aspiration versus stereotactic aspiration 
versus craniotomy15). Ninety non-comatose patients with basal 
ganglia ICH were randomized into three groups. In this study, 
both endoscopic aspiration and stereotactic aspiration showed 
lower complication rates and lower mortality at 3 months and 
better neurologic outcomes at 6 months after surgery. However, 
the delayed time for stereotactic aspiration was usually longer 
than that of endoscopic surgery. Endoscopic surgery was more 
cost-effective than craniotomy using functional independence 
manner and BI. 
A meta-analysis of high-quality RCTs regarding minimally in-
vasive surgery (stereotactic aspiration or endoscopic surgery) for 
spontaneous supratentorial ICH has been recently published78). 
This study with 1955 patients from 12 high-quality randomized 
controlled trials concluded that patients with supratentorial ICH 
might benefit more from minimally invasive surgery than from 
other treatment options. The most beneficial subgroups were 
both sexes, 30 to 80 years of age with a superficial hematoma, a 
GCS score of ≥9, a hematoma volume between 25 mL and 40 
mL, and within 72 hours after onset of symptoms78).
IVH
IVH coincides with ICH in 40% of patients with primary ICH25). 
IVH is comprised of primary IVH, which is confined to the ven-
tricles, and secondary IVH which is an extension of an ICH due 
to hypertensive ICH or vascular malformation in the basal gan-
glia and the thalamus20,25). Conventional management of IVH is 
the use of an EVD to remove blood clots in the ventricles and to 
treat obstructive hydrocephalus. Theoretically, EVD via VC can 
be helpful to drain blood and cerebrospinal fluid from the clot-
ted ventricles, but an EVD alone is often inadequate for an IVH 
because the catheter becomes occluded with blood clots, and it 
takes so much time for blood clots to be clearly reduced that a 
longer indwelling of the catheter does not prevent inflammatory 
reactions caused by the breakdown of blood clots in the ventri-
cles, which often leads to communicating hydrocephalus29). Thus, 
the administration of fibrinolytic agents through a VC has at-
tracted a lot of attention recently. Several reports from animal 
studies and clinical series suggested that intraventricular admin-
istration of fibrinolytic agents, including urokinase, streptoki-
nase, and recombinant tPA, may reduce morbidity and mortality 
by accelerating blood clearance in IVH21,43,55,56,58,62). The Clot Ly-
sis, Evaluating Accelerated Resolution of IVH (CLEAR-IVH) Tri-
al, prospectively was designed to evaluate the safety and efficacy 
of using 1.0 mg injections of recombinant tPA through an EVD 
every 8 hours up to 9 doses to accelerate lysis and evacuation of 
the IVH, and is still ongoing48). In the preliminary report pub-
lished in 2008, the average clot reduction after the acute treat-
ment phase was 46%, and the 30-day mortality rate was 8%, while 
symptomatic rebleeding occurred in 4%, and bacterial ventricu-
litis in 0%48). 
New recommendations 
1. If there is deterioration of consciousness due to mass effect 
from the hematoma, an early craniotomy may be considered (LOE 
IV, GOR C) (revised recommendation).
2. A craniotomy should be considered for a lobar hemorrhage 
located within 1 cm from the surface with a consciousness level 
of 9–12 on the GCS (LOE IIb, GOR B).
3. For supratentorial ICH with a GCS score of 9 or over, with a 
hematoma volume between 25 and 40 mL, and within 72 hours 
after onset of symptoms, minimally invasive surgery for evacua-
tion of the hematoma is recommended (LOE IIb, GOR B) (new 
recommendation).
4. A craniotomy is recommended for a cerebellar hemorrhage 
with a maximal diameter of 3 cm or longer or for symptoms sug-
gestive of brainstem compression or hydrocephalus (LOE IIb, 
GOR B) (revised recommendation).
5. For IVH, thrombolysis via the ventricular puncture may be 
considered (LOE IV, GOR C).
CONCLUSION
CPGs based on scientific evidence are presented for the med-
ical and surgical management of patients presenting with prima-
ry ICH. This CPG describes the current pertinent recommenda-
tions and suggests Korean recommendations for the medical 
and surgical management of a patient with primary ICH.
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